Bluejay Therapeutics, Inc.

Hepatitis D has so far largely resisted pharmaceutical intervention, with only one specifically approved product and several high-profile failures underlining the disease’s intractability. However, mi

With rising interest in inflammation and immunology – likely in response to large deals in the I&I space as much as unmet needs in autoimmune diseases – venture capital investors have put big money in

Esepapogene zalarnarepvec, Hookipa Pharma ’s investigational treatment for human papillomavirus 16-positive oropharyngeal cancer, is among the latest three products that have made it onto PRIME, the

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Bristol, VantAI Pair Technologies In Pr